Trial Profile

A Two-arm Multi-stage (TAMS) Seamless Phase II/III Randomised Trial of Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC

Status: Suspended

Phase of Trial: Phase II/III

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Liver cancer
Focus Therapeutic Use
Acronyms TACE-3

Most Recent Events

26 Feb 2025 Planned End Date changed from 1 Jun 2026 to 30 Jun 2026.
26 Feb 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Aug 2025.
26 Feb 2025 Status changed from recruiting to suspended because analysis meant the study should close to recruitment.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com